Penumbra (PEN) vs West Pharmaceutical Services (WST)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
West Pharmaceutical Services (WST) has outperformed Penumbra (PEN) over the past year, gaining 37.8% versus a gain of 27.0%. Over five years, PEN leads with a +18.2% price change compared with -9.5% for WST. West Pharmaceutical Services is the larger company by market cap ($25.79 billion vs $12.46 billion), about 2.1 times the size, while Penumbra is growing revenue faster (+17.5% vs +6.3%).
On valuation, West Pharmaceutical Services trades at a lower forward P/E (36.7x vs 51.6x for Penumbra). West Pharmaceutical Services pays a dividend yielding 0.24%, while Penumbra does not currently pay one. West Pharmaceutical Services converts more of its revenue into profit, with a net margin of 16.1% versus 12.7%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PEN | WST |
|---|---|---|
| Share price | $316.35 | $366.48 |
| Market cap | $12.46B | $25.79B |
| 1-day change | -0.22% | -1.65% |
| YTD return | +1.75% | +33.20% |
| 1-year return | +27.03% | +37.79% |
| 5-year return | +18.15% | -9.47% |
| P/E ratio (TTM) | 77.73 | 46.92 |
| Forward P/E | 51.59 | 36.72 |
| EPS (TTM) | $4.07 | $7.81 |
| Dividend yield | 0.00% | 0.24% |
| Annual dividend | $0.00 | $0.87 |
| Revenue (latest FY) | $1.40B | $3.07B |
| Revenue growth (YoY) | +17.50% | +6.25% |
| Net income (latest FY) | $177.69M | $493.70M |
| Gross margin | 67.14% | 35.91% |
| Operating margin | 13.48% | 19.03% |
| Net margin | 12.66% | 16.06% |
| 52-week high | $362.41 | $386.00 |
| 52-week low | $221.26 | $223.83 |
| Distance from 52-week high | -12.71% | -5.06% |
| Analyst consensus | hold | strong_buy |
| Avg. price target upside | +14.30% | +12.15% |
| Average volume | 343.03K | 629.98K |
| Shares outstanding | 39.39M | 70.38M |
| Employees | 4,700 | 10,800 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- West Pharmaceutical Services is about 2.1 times larger than Penumbra by market value ($25.79B vs $12.46B).
- WST has outperformed PEN by 10.8 percentage points over the past year.
- Penumbra trades at a higher earnings multiple (77.7x vs 46.9x trailing P/E).
- Penumbra grew revenue faster in its latest fiscal year (+17.50% vs +6.25%).
About Penumbra
PEN stock →Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.
Health Care · Medical/Dental Instruments · 4,700 employees
About West Pharmaceutical Services
WST stock →West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific.
Health Care · Medical/Dental Instruments · 10,800 employees
PEN vs WST FAQ
Which is bigger, Penumbra or West Pharmaceutical Services?
West Pharmaceutical Services (WST) is larger, with a market capitalization of $25.79B compared with $12.46B for Penumbra (PEN).
Which stock has performed better over the past year, PEN or WST?
WST returned +37.79% over the past 12 months, compared with +27.03% for PEN (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, PEN or WST?
WST has the lower trailing P/E at 46.9, versus 77.7 for PEN. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Penumbra or West Pharmaceutical Services?
West Pharmaceutical Services pays a dividend yielding 0.24%, while Penumbra does not currently pay a regular dividend.
Are Penumbra and West Pharmaceutical Services in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.